NARA Discovery
Article Details
← Back to Search Results
Journal Article

Design, synthesis, and anti-breast cancer activity evaluation of novel 3-cyanopyridine derivatives as PIM-1 inhibitors

Bahgat R. M. Hussein; Hayam H. Mohammed; Eman A. Ahmed; Omar Alshazly; Mamdouh F. A. Mohamed; Omran A. Omran
Molecular Diversity · Vol. 29, Issue 3 · pp. 2565-2584 · 2025

Abstract

A novel series of cyanopyridines 7a-j were synthesized via a one-pot multicomponent reaction of arylidene 4 with ammonium acetate 5 and respective methylaryl/heterylketones 6a-j in ethanol using vanillin as a natural starting material. Moreover, the regioselective alkylation reaction was studied by the treatment of cyanopyridines 7a-f and 7j with CH 3 I in the presence of K 2 CO 3 in DMF to afford O -methylcyanopyridines 8a-g (major) and N -methylcyanopyridines 9a-g (minor), whereas bipyridine 7h gave bipyridinium iodide salt 10 . All of the designed cyanopyridines were evaluated as anti-breast cancer (MCF-7) cell lines via PIM Kinase inhibitory activity, and the results displayed that some of them showed high activities, especially compounds 7h and 8f , which showed excellent activities against MCF-7 with IC 50 values of 1.89 and 1.69 μM, respectively, more potent than the reference drug doxorubicin. Mechanistically, compounds 7h and 8f exhibited strong in vitro PIM-1 kinase inhibitory activity with an IC 50 of 0.281 and 0.58 μM, respectively, compared to the reference staurosporine. Moreover, compound 7h arrested the tumor cells at the S phase and caused cell death mainly by inducing early and late apoptosis. Molecular docking studies against PIM-1 revealed good binding modes of the synthesized compound and showed agreement with the biological results. Graphical abstract

Bibliographic Information

JournalMolecular Diversity
PublisherSpringer
Publication Date2025-06-01
Publication Year2025
Volume29
Issue3
Pages2565-2584
Document TypeJournal Article
eISSN1573-501X
DOI10.1007/s11030-024-11010-8

Access Information

NARA Access Coverage1995-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11030
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.